SCHEDULE 13G/A: FMR LLC and Abigail P. Johnson Disclose 5.2% Stake in 10x Genomics Class A Common Stock

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, reporting a beneficial ownership of 5.2% of 10x Genomics, Inc.'s Class A Common Stock as of April 30, 2025.

Summary

• FMR LLC and Abigail P. Johnson collectively beneficially own 5,647,992.62 shares of 10x Genomics, Inc. Class A Common Stock.
• This ownership represents 5.2% of the outstanding Class A Common Stock.
• The reported beneficial ownership includes 2,274,876 shares of Class B Common Stock, which are convertible into Class A Common Stock at a 1:1 exchange rate.
• These Class B shares constitute 16.536% of the total outstanding Class B Common Stock.
• Assuming the conversion of all outstanding Class B Common Stock into Class A Common Stock, the reported beneficial ownership would represent 4.586% of the total outstanding Class A Common Stock.
• FMR LLC holds sole voting power over 5,626,652.00 shares and sole dispositive power over 5,647,992.62 shares.
• Abigail P. Johnson holds sole dispositive power over 5,647,992.62 shares.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of 10x Genomics, Inc.

Sentiment

Score: 5

Explanation: Neutral. This is a routine disclosure of beneficial ownership by a major institutional investor, providing transparency without indicating positive or negative performance or strategic shifts.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, which can influence investor confidence and market perception.

Key Dates

Keywords

10x Genomics, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Class A Common Stock, Institutional Investor, SEC Filing, Biotechnology, Life Sciences